Early Termination of the Trial

EudraCT No:	**2021-001030-19**
Protocol No:	**FP2CLI003**
Protocol Title:	**A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma (MATINS RENACOL)**
Sponsor:	**Faron Pharmaceuticals Ltd, Finland**

The Sponsor made the decision to terminate the trial early on 28 Jan 2022. The rationale is based upon the following:

The primary objective of the MATINS RENACOL study was to evaluate the safety and tolerability of a single dose of bexmarilimab given in the neoadjuvant setting. The study protocol was submitted to Fimea in April 2021, and the study opened for enrollment in October 2021. Meanwhile, another ongoing Faron sponsored trial has enrolled and treated numerous patients with bexmarilimab. Given that no patients have been enrolled in RENACOL, and that safety and tolerability data is rapidly accumulating in another ongoing study, the Sponsor considered that the RENACOL study is no longer needed to assess the safety profile of bexmarilimab.

Faron Pharmaceuticals Ltd
Joukahaisenkatu 6, FI-20520 Turku, Finland
Tel. +358 2 469 5151
Fax: +358 2 469 5152
www.faron.com
Business ID 2068285-4, Domicile Turku